Table 1.
Patient demographics and overall sample breakdown
| Characteristic | Overall sample breakdown (N = 77) |
| Sex | |
| Male | 49 (63.63%) |
| Female | 28 (36.36%) |
| Age | |
| Mean age ± SD | 56.21 ± 15.52 |
| Age > 40 | 68 (88.31%) |
| Age > 50 | 53 (68.83%) |
| Age > 60 | 35 (45.45%) |
| Race | |
| Asian | 3 (3.90%) |
| American Indian or Alaskan Native | 2 (2.60%) |
| Black or African | 27 (35.06%) |
| Hispanic | 11 (14.29%) |
| White | 26 (33.77%) |
| Others | 8 (10.39%) |
| Ethnicity | |
| Hispanic | 20 (25.97%) |
| Not Hispanic | 57 (74.03%) |
| Education level | |
| 8th grade or less | 11 (14.29%) |
| High school | 28 (36.36%) |
| College or greater | 38 (49.35%) |
| Eye disease category | |
| Age-related macular degeneration | 4 (5.19%) |
| Diabetic retinopathy | 35 (45.45%) |
| Age-related cataracts | 66 (85.71%) |
| Glaucoma | 10 (12.99%) |
| Epiretinal membrane | 17 (22.08%) |
| Retinal detachment | 32 (41.56%) |
| Macular hole | 12 (15.58%) |
| APOE allele | Overall sample breakdown (n = 76, 152 alleles) |
| ε2 (may offer some protection against AD) | 15 (9.87%) |
| ε3 (neutral risk for AD) | 121 (79.61%) |
| ε4 (increases risk for AD at an earlier age) | 16 (10.52%) |
| APOE genotype | Overall sample breakdown (n = 77) |
| ε22 | 0 (0.0%) |
| ε23 | 11 (14.29%) |
| ε24 | 4 (5.19%) |
| ε33 | 45 (58.44%) |
| ε34 | 16 (20.78%) |
| ε44 | 0 (0.0%) |
| MMSE scores, mean ± SD | Mean ± SD (n = 77) |
| No cognitive impairment (n = 68) | 27.91 ± 1.68 |
| Mild or severe cognitive impairment (n = 9) | 19.44 ± 2.35 |
APOE apolipoprotein E